Skip to main content

Table 2 comparison of composite unfavorable outcome (primary outcome) and successful TB treatment (secondary outcome) between Nevirapine and Efavirenz

From: Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study

  Center 1 Center 2 Combined data
Nevirapine (n = 67) (%) Efavirenz (n = 74) (%) Effect size (95% CI) Nevirapine (n = 77) (%) Efavirenz (n = 66) (%) Effect size (95% CI) Nevirapine (n = 144) (%) Efavirenz (n = 140) (%) Effect size (95% CI)
Composite unfavorable outcome
Unadjusted 30 (44.8%) 29 (39.2%) 5.6% (−10.7,21.9) 19 (24.7%) 22 (33.3%) −8.7% (−23.6,6.2) 49 (34%) 51 (36.4%) −2.4% (−13.5,8.7)
Adjusted for stage 44.1% 39.7% −7.8% (−33.3,7.7) 26.2% 34.8% 4% (−6.4,14.5) 35.3% 36.9% 4.5% (−5.1,14)
ART failure
Unadjusted 20 (29.9%) 22 (29.7%) 1.2% (−15,15) 19 (24.7%) 20 (30.3%) −5.6% (−20.7,9.1) 40 (27.8%) 43 (30.7%) −2.9% (−13.5,8.7)
Adjusted for stage 29.5% 30% −4.3% (−28,19.5) 27.5% 33.2% 2.8% (−7.7,13.3) 28.7% 31.3% 13.2% (−7.8,10.5)
Death
Unadjusted 13 (19.4%) 10 (13.5%) 5.9% (−6.4,18.2) 6 (7.8%) 7 (10.6%) −2.8% (−12.4,6.7) 19 (13.2%) 17 (12.1%) 1.1% (−6.7,8.8)
Adjusted for stage 18.4% 14.4% −11.7% (−30.7,7.3) 8.2% 11.1% 0.05% (−6.7,6.8) 13.6% 12.4% −0.2 (−6.9,6.4)
Successful TB treatment at 48 weeks
Unadjusted 39 (58.2%) 39 (52.7%) 5.5% (−10.9,22) 63 (81.8%) 51 (77.3%) 4.5% (−7.6,18.8) 102 (71.3%) 90 (64.3%) 7% (−3.8,17.9)
Adjusted for stage 59.4% 51.6% 15.2% (−10.4,40.8) 84.6% 79.5% −4.1% (−12.8,4.7) 71.5% 65.6% −7% (−16.2,2.2)